Look for:

Products

REGENERON PHARMACEUTICALS INC.


ISIN:
US75886F1075
WKN:
75886F107

2024/05/24 22:00:00
Price
985.02 USD
Difference 0.45% (4.45)

General attributes

ISINUS75886F1075
SymbolREGN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)98,413 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)965.00 USD (100)
Ask (Ask size)1,098.93 USD (100)
Open984.04 USD
High995.405 USD
Low983.16 USD
Close (prev. day)980.57 USD
VWAP986.974059 USD
Volume (pcs)259,279
Trading volume256,071,546.57
Number of trades13,457
Last size-

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: REGENERON PHARMACEUTICALS INC.PDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2024/05/24 22:00:00
Price
985.02 USD
Difference 0.45% (4.45)

General attributes

ISINUS75886F1075
SymbolREGN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)98,413 EUR
BenchmarkS&P 500

Market data

Bid (Bid size)965.00 USD (100)
Ask (Ask size)1,098.93 USD (100)
Open984.04 USD
High995.405 USD
Low983.16 USD
Close (prev. day)980.57 USD
VWAP986.974059 USD
Volume (pcs)259,279
Trading volume256,071,546.57
Number of trades13,457
Last size-

Performance and Risk

6m1Y3Y
Perf (%)+23.39%+33.58%+96.82%
Perf (abs.)+186.72+247.62+484.55
Beta0.480.460.57
Volatility17.0820.0427.12
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)986.12 USD (306,632)
Ø price 30 days | Ø volume 30 days (pcs.)940.02 USD (444,979)
Ø price 100 days | Ø volume 100 days (pcs.)946.99 USD (472,817)
Ø price 250 days | Ø volume 250 days (pcs.)857.09 USD (519,146)
YTD High | date998.33 USD (2024/02/28)
YTD Low | date871.39 USD (2024/01/02)
52 Weeks High | date998.33 USD (2024/02/28)
52 Weeks Low | date684.81 USD (2023/06/28)

Arbitrage views

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Xetra2023/10/2017:35766.50 EUR0.0918
Vienna Stock Exchange2024/05/2417:32911.40 EUR0.002
Tradegate2024/05/2422:26907.80 EUR0.026
Stuttgart2024/05/2419:38910.20 EUR0.006
Nasdaq2024/05/2422:00985.02 USD256.0713,457
Munich2024/05/2408:09909.80 EUR0.002
London Stock Exchange2024/05/1016:46975.08 USD0.071
Hanover2024/05/2410:41901.20 EUR0.003
Hamburg2024/05/2408:11902.00 EUR0.003
Frankfurt2024/05/2409:43910.80 EUR0.001
Euronext Milan MTF Trading After Hours2024/03/0618:32895.00 EUR0.001
Euronext Milan MTF Global Equity Market2024/05/2417:44910.60 EUR0.002
Duesseldorf2024/05/2408:10899.20 EUR0.003
Berlin2024/05/2408:09902.80 EUR0.002

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=99472&ID_TYPE_IMAGE_LOGO=2

Contact Details

REGENERON PHARMACEUTICALS INC.
- -
777 Old Saw Mill River Road - 10591-6707 Tarrytown
Telefon: +1-914-847-7000
Fax: +
E-mail: usinfo@regeneron.com

PDF Downloads

Company report: REGENERON PHARMACEUTICALS INC.PDF Download

Company Profile

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Members of Management Board

George YancopoulosChairman of Board of Directors
Bonnie BasslerMember of Board of Directors
Craig ThompsonMember of Board of Directors
David SchenkeinMember of Board of Directors
Huda ZoghbiMember of Board of Directors
Joseph GoldsteinMember of Board of Directors
Kathryn GuariniMember of Board of Directors
Michael BrownMember of Board of Directors
N. ColesMember of Board of Directors
Arthur RyanMember of Board of Directors
Christine PoonMember of Board of Directors
George SingMember of Board of Directors
Leonard S. SchleiferChairman of Managing Board
George D. YancopoulosMember of Executive Committee
Bob McCowanMember of Executive Committee
Joseph J. LaRosaMember of Executive Committee
Marion McCourtMember of Executive Committee
Melissa LoznerMember of Executive Committee
Robert E. LandryMember of Executive Committee
Sally A. PaullMember of Executive Committee
Smita PillaiMember of Executive Committee






Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR CORPORATE AND INSTITUTIONAL CLIENTS

Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).

The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.

Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended), citizen/resident of Australia, Canada, Great Britain and Japan. For this reason, the distribution or redistribution of the information, materials and products into United States, Australia, Canada, Great Britain and Japan or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited.

The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.

The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.

By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.
(iV) It is no consumer.